Cyprumed is a drug delivery technology company based in Innsbruck, Austria. The company focuses on developing technology platforms for the oral administration of therapeutic peptides, including GLP‑1 analogues, macrocycles and mini-proteins. Cyprumed’s proprietary delivery platforms feature innovative tablet formulations that offer superior oral bioavailability and build on already approved pharmaceutical excipients, thus improving scalability, cost-efficiency and regulatory compliance. Cyprumed aims to transform peptide therapeutics by providing easy to manufacture, patient-friendly oral dosage forms.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.